Skip to main content

Drug Discovery and Delivery NEtwork for ONcology and Eye Therapeutics

Objective

Severe ocular disorders are affecting the lives of more than 100Mill people world-wide and at least 25% of the population above 70 years of age, a growing demographic group in EU. More than 8 million people lose their lives to cancer every year, making cancer a leading cause of pre-mature mortality in the world. The main hallmarks of severe eye conditions (i.e angiogenesis, inflammation and vascular permeability) play also pivotal roles in cancer, being therapeutic targets to treat both kind of diseases.

The overall goal of 3D-NEONET is the improvement of available treatments for cancer and ocular disease by enhancing drug discovery-development and delivery to targeted tissues, through advanced international co-operation between academic and non-academic partners. The interdisciplinary expertise provided by 18 partners in 7 countries encompasses among others: drug screens, ADME, toxicology, preclinical models, nanotechnology, biomaterials and clinical trials.

After the success with ongoing FP7-IAPP project 3D-NET (Drug Discovery and Development of Novel Eye Therapeutics; (www.ucd.ie/3dnet), we are assembling 3D-NEONET, this enlarged European interdisciplinary consortium that will join forces and exchange skills to enhance current therapies in oncology and ophthalmology.
The 3 global objectives of 3D-NEONET are:
1- Enhance the discovery and development of novel drugs, targets and biomarkers for ophthalmology and oncology.
2- Improve the Delivery of Therapeutics for Oncology and Ophthalmology
3- Enhancement of Research, Commercial and Clinical Trial Project Management Practices in these fields.

Through participation in the program, 3D-NEONET is the vehicle for driving synergies between academic and non-academic partners leading to increased scientific and technological excellence as well as tangible innovative outputs that will strengthen the competitiveness of both the researchers and industries of the network even beyond the lifetime of the network.

Field of science

  • /medical and health sciences/clinical medicine/ophthalmology/retinopathy
  • /medical and health sciences/clinical medicine/cancer/prostate cancer
  • /medical and health sciences/clinical medicine/cancer/breast cancer
  • /medical and health sciences/clinical medicine/ophthalmology/glaucoma

Call for proposal

H2020-MSCA-RISE-2016
See other projects for this call

Funding Scheme

MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)

Coordinator

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Address
Belfield
4 Dublin
Ireland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 200 475

Participants (20)

UNIVERSIDAD DE VALLADOLID
Spain
EU contribution
€ 9 000
Address
Plaza Santa Cruz 8 Palacio De Santa Cruz
47002 Valladolid
Activity type
Higher or Secondary Education Establishments
LINKOPINGS UNIVERSITET
Sweden
EU contribution
€ 70 065
Address
Campus Valla
581 83 Linkoping
Activity type
Higher or Secondary Education Establishments
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Ireland
EU contribution
€ 31 500
Address
College Green
2 Dublin
Activity type
Higher or Secondary Education Establishments
LABORATORIO IBERICO INTERNACIONAL DE NANOTECNOLOGIA
Portugal
EU contribution
€ 56 250
Address
Avenida Mestre Jose Veiga Congredados
4715 330 Braga
Activity type
Research Organisations
NATIONAL UNIVERSITY OF IRELAND GALWAY
Ireland
EU contribution
€ 31 500
Address
University Road
H91 Galway
Activity type
Higher or Secondary Education Establishments
THE QUEEN'S UNIVERSITY OF BELFAST
United Kingdom
EU contribution
€ 47 790
Address
University Road Lanyon Building
BT7 1NN Belfast
Activity type
Higher or Secondary Education Establishments
UNIVERSIDAD COMPLUTENSE DE MADRID
Spain
EU contribution
€ 72 000
Address
Avenida De Seneca 2
28040 Madrid
Activity type
Higher or Secondary Education Establishments
KARLSRUHER INSTITUT FUER TECHNOLOGIE
Germany
EU contribution
€ 4 950
Address
Kaiserstrasse 12
76131 Karlsruhe
Activity type
Higher or Secondary Education Establishments
ZECLINICS SL
Spain
EU contribution
€ 9 000
Address
Ctra De Can Ruti, Cami De Les Escoles, S/n Laboratori P0-8, Edifici Igtp Muntanya
08916 Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
HGBEYOND MATERIALS SICENCE SL
Spain
EU contribution
€ 13 500
Address
Edificio Emprendia
15782 Santiago De Compostela
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EXPERIMENTELLE PHARMAKOLOGIE UND ONKOLOGIE BERLIN-BUCH GMBH

Participation ended

Germany
EU contribution
€ 0
Address
Robert-roessle-strasse 10
13125 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
XENOPAT SL
Spain
EU contribution
€ 18 000
Address
Calle Feixa Llarga S/n Edifici Bioincuoadora
08907 Hospitalet De Llobregat
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ECM INGENIERIA AMBIENTAL SL
Spain
EU contribution
€ 50 850
Address
C/curtidores 17
34004 Palencia
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ICON CLINICAL RESEARCH LIMITED
Ireland
EU contribution
€ 0
Address
South County Business Park Leopardstown
18 Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
OCUPHARM DIAGNOSTICS SL
Spain
EU contribution
€ 298 620
Address
Francisco Silvela 88 7B
28002 Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ASHLAND SPECIALTIES IRELAND LIMITED

Participation ended

Ireland
EU contribution
€ 0
Address
National Science Park, Building V, Dublin Road, Petitswood
N91 F6PD Mullingar, Westmeath
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
BLAFAR LIMITED
Ireland
EU contribution
€ 22 500
Address
1 Clonfadda Wood Mount Merriion Avenue
A94W1K6 Blackrock Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
WATERFORD INSTITUTE OF TECHNOLOGY
Ireland
EU contribution
€ 9 000
Address
Cork Road
X91 Waterford
Activity type
Higher or Secondary Education Establishments
BIOREPERIA AB
Sweden
EU contribution
€ 0
Address
Westmansgatan 47 3Tr
582 16 Linkoping
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CRESSET BIOMOLECULAR DISCOVERY LIMITED
United Kingdom
EU contribution
€ 0
Address
New Cambridge House Bassingbourn Road
SG8 0SS Litlington
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)

Partners (1)

EYECRO LLC
United States
Address
800 Research Parkway, Suite 360
73104 Oklahoma City
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)